Skip to main content
. 2023 Jul 15;129(8):1212–1224. doi: 10.1038/s41416-023-02361-4

Fig. 3. Schematic depiction of proposed novel technologies aimed at restoring T-cell generation by reinvigorating DCs immunogenicity in desert tumours.

Fig. 3

a GVAX vaccine enhances both systemic and localised GM-CSF levels to re-establish immunogenic functions of monocyte-derived DCs for the generation of anti-tumour T cells. b TriMix, an mRNA-based gene-therapy vaccine to reinvigorate the immunological synapse by restoring levels of co-stimulatory molecules in immunosuppressed DCs, thereby improving the priming of anti-tumour T cells. c Disrupting MIF engagement with multiple targets using 4-ipp MIF inhibitor regulates lactate metabolism within tumour cells, consequently augmenting anti-CTLA-4 response. d Blocking the MIF/CD74 immunosuppressive axis in DCs using C36L1 therapeutic peptide restores immunogenic phenotype and unleashes the priming of anti-tumour T cells and cancer immunosurveillance. e Tebentafusp triggers immune activation in T-cell desert tumours, such as mUM. f Clinical-grade precision genome editing facilitates the deactivation of inherent TCR genes and the integration of neoantigen-specific TCR chains for clonal expansion of anti-tumour T cells.